Mirum Pharmaceuticals, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDMirum Pharmaceuticals, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is moderate (RS Rating: 78), indicating performance broadly in line with the market. Earnings contraction of 44% provides fundamental context to the price action. Momentum will need to be maintained above the 50-day moving average to sustain this leadership phase.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $97.24 | +5.86% | ABOVE |
| 50 SMA | $93.78 | +9.76% | ABOVE |
| 100 SMA | $92.33 | +11.48% | ABOVE |
| 150 SMA | $85.21 | +20.80% | ABOVE |
| 200 SMA | $80.74 | +27.48% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is MIRM in an uptrend right now?
MIRM has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, MIRM is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is MIRM overbought or oversold?
MIRM's RSI (14) is 74. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is MIRM outperforming the market?
MIRM has a Relative Strength (RS) Rating of 78 out of 99. MIRM is performing about average compared to the market.
Where is MIRM in its 52-week range?
MIRM is trading at $102.93, which is 92% of its 52-week high ($112.00) and 87% above its 52-week low ($40.00).
How volatile is MIRM?
MIRM has a Beta of 1.02 and 52-week volatility of 43%. It's more volatile than the S&P 500 - expect bigger swings.